


## **LEVOCARNITINE- levocarnitine tablet Akorn**

### **Levocarnitine Tablets USP (330 mg)**

#### **DESCRIPTION**

Levocarnitine is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane.

The chemical name of levocarnitine is 3-carboxy-2(*R*)-hydroxy-*N,N,N*-trimethyl-1-propanaminium, inner salt. Levocarnitine is a white crystalline, hygroscopic powder. It is readily soluble in water, hot alcohol, and insoluble in acetone. The specific rotation of levocarnitine is between  $-29^{\circ}$  and  $-32^{\circ}$ . Its chemical structure is:



Empirical Formula: C<sub>7</sub>H<sub>15</sub>NO<sub>3</sub>

Molecular Weight: 161.20

Each Levocarnitine Tablet USP contains 330 mg of levocarnitine and the inactive ingredients magnesium stearate, microcrystalline cellulose and povidone.

#### **CLINICAL PHARMACOLOGY**

Levocarnitine is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production.

Primary systemic carnitine deficiency is characterized by low concentrations of levocarnitine in plasma, RBC, and/or tissues. It has not been possible to determine which symptoms are due to carnitine deficiency and which are due to an underlying organic acidemia, as symptoms of both abnormalities may be expected to improve with levocarnitine. The literature reports that carnitine can promote the excretion of excess organic or fatty acids in patients with defects in fatty acid metabolism and/or specific organic acidopathies that bioaccumulate acylCoA esters.<sup>1-6</sup>

Secondary carnitine deficiency can be a consequence of inborn errors of metabolism. Levocarnitine may alleviate the metabolic abnormalities of patients with inborn errors that result in accumulation of toxic organic acids. Conditions for which this effect has been demonstrated are: glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency.<sup>7,8</sup> Autointoxication occurs in these patients due to the accumulation of acylCoA compounds that disrupt

intermediary metabolism. The subsequent hydrolysis of the acylCoA compound to its free acid results in acidosis which can be life-threatening. Levocarnitine clears the acylCoA compound by formation of acylcarnitine, which is quickly excreted. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20  $\mu\text{mol/L}$  at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. In premature infants and newborns, secondary deficiency is defined as plasma levocarnitine concentrations below age-related normal concentrations.

## PHARMACOKINETICS

In a relative bioavailability study in 15 healthy adult male volunteers, levocarnitine tablets were found to be bio-equivalent to levocarnitine oral solution. Following 4 days of dosing with 6 tablets of levocarnitine 330 mg b.i.d. or 2 g of levocarnitine oral solution b.i.d., the maximum plasma concentration ( $C_{\text{max}}$ ) was about 80  $\mu\text{mol/L}$  and the time to maximum plasma concentration ( $T_{\text{max}}$ ) occurred at 3.3 hours.

The plasma concentration profiles of levocarnitine after a slow 3 minute intravenous bolus dose of 20 mg/kg of levocarnitine were described by a two-compartment model. Following a single i.v. administration, approximately 76% of the levocarnitine dose was excreted in the urine during the 0-24h interval. Using plasma concentrations uncorrected for endogenous levocarnitine, the mean distribution half life was 0.585 hours and the mean apparent terminal elimination half life was 17.4 hours.

The absolute bioavailability of levocarnitine from the two oral formulations of levocarnitine, calculated after correction for circulating endogenous plasma concentrations of levocarnitine, was  $15.1 \pm 5.3\%$  for levocarnitine tablets and  $15.9 \pm 4.9\%$  for levocarnitine oral solution.

Total body clearance of levocarnitine (Dose/AUC including endogenous baseline concentrations) was a mean of 4.00 L/h.

Levocarnitine was not bound to plasma protein or albumin when tested at any concentration or with any species including the human.<sup>9</sup>

## METABOLISM AND EXCRETION

In a pharmacokinetic study where five normal adult male volunteers received an oral dose of [ $^3\text{H}$ -methyl]-L-carnitine following 15 days of a high carnitine diet and additional carnitine supplement, 58 to 65% of the administered radioactive dose was recovered in the urine and feces in 5 to 11 days. Maximum concentration of [ $^3\text{H}$ -methyl]-L-carnitine in serum occurred from 2.0 to 4.5 hr after drug administration. Major metabolites found were trimethylamine N-oxide, primarily in urine (8% to 49% of the administered dose) and [ $^3\text{H}$ ]- $\gamma$ -butyrobetaine, primarily in feces (0.44% to 45% of the administered dose). Urinary excretion of levocarnitine was about 4 to 8% of the dose. Fecal excretion of total carnitine was less than 1% of the administered dose.<sup>10</sup>

After attainment of steady state following 4 days of oral administration of levocarnitine tablets (1980 mg q12h) or oral solution (2000 mg q12h) to 15 healthy male volunteers, the mean urinary excretion of levocarnitine during a single dosing interval (12h) was

about 9% of the orally administered dose (uncorrected for endogenous urinary excretion).

## **INDICATIONS AND USAGE**

Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient.

Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.

## **CONTRAINDICATIONS**

None known.

## **WARNINGS**

### **Hypersensitivity Reactions**

Serious hypersensitivity reactions, including rash, urticaria, and facial edema have been reported with oral levocarnitine. Other serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following intravenous levocarnitine administration, mostly in patients with end stage renal disease undergoing dialysis.

Discontinue use of levocarnitine and instruct patients to seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction.

## **PRECAUTIONS**

### **General**

The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine.

### **Drug Interactions**

Reports of INR increase with the use of warfarin have been observed. It is

recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.

### **Carcinogenesis, mutagenesis, impairment of fertility**

Mutagenicity tests performed in *Salmonella typhimurium*, *Saccharomyces cerevisiae*, and *Schizosaccharomyces pombe* indicate that levocarnitine is not mutagenic. No long-term animal studies have been performed to evaluate the carcinogenic potential of levocarnitine.

### **Pregnancy**

Reproductive studies have been performed in rats and rabbits at doses up to 3.8 times the human dose on the basis of surface area and have revealed no evidence of impaired fertility or harm to the fetus due to levocarnitine. There are, however, no adequate and well controlled studies in pregnant women.

Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

### **Nursing mothers**

Levocarnitine supplementation in nursing mothers has not been specifically studied.

Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment.

### **Pediatric use**

See DOSAGE AND ADMINISTRATION.

## **ADVERSE REACTIONS**

The following adverse reactions associated with the use of oral formulations of levocarnitine were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliability, or to establish a causal relationship to drug exposure.

*Gastrointestinal Reactions:* Various mild gastrointestinal complaints have been reported during the long-term administration of oral L- or D,L-carnitine; these include transient nausea and vomiting, abdominal cramps, and diarrhea. Decreasing the dosage often diminishes or eliminates drug-related patient body odor or gastrointestinal symptoms when present. Tolerance should be monitored very closely during the first week of administration, and after any dosage increases.

*Musculoskeletal Reactions:* Mild myasthenia has been described only in uremic patients receiving D,L-carnitine.

*Neurologic Reactions:* Seizures have been reported to occur in patients with or without pre-existing seizure activity receiving either oral or intravenous levocarnitine. In patients

with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported.

*Hypersensitivity Reactions:* Rash, urticaria, and facial edema have been reported with oral levocarnitine (see WARNINGS).

## **OVERDOSAGE**

There have been no reports of toxicity from levocarnitine overdose. Levocarnitine is easily removed from plasma by dialysis. The intravenous LD<sub>50</sub> of levocarnitine in rats is 5.4 g/kg and the oral LD<sub>50</sub> of levocarnitine in mice is 19.2 g/kg. Large doses of levocarnitine may cause diarrhea.

## **DOSAGE AND ADMINISTRATION**

### Levocarnitine Tablets USP

Adults: The recommended oral dosage for adults is 990 mg two or three times a day using the 330 mg tablets, depending on clinical response.

Infants and children: The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response.

Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.

## **HOW SUPPLIED**

Levocarnitine Tablets USP are supplied as 330 mg tablets embossed with "LC 77" in individual blisters, packaged in boxes of 90 (NDC 50383-172-90). Store at controlled room temperature (25°C). See USP. Levocarnitine Tablets USP are distributed by Hi-Tech Pharmacal Co., Inc., Amityville, NY 11701.

**Rx only.**

## **REFERENCES**

1. Bohmer, T., Rydning, A. and Solberg, H.E. 1974. Carnitine levels in human serum in health and disease. *Clin. Chim. Acta* 57:55-61.
2. Brooks, H., Goldberg, L., Holland, R. *et al.* 1977. Carnitine-induced effects on cardiac and peripheral hemodynamics. *J. Clin. Pharmacol.* 17:561-568.
3. Christiansen, R., Bremer, J. 1976. Active transport of butyrobetaine and carnitine into isolated liver cells. *Biochim. Biophys. Acta* 448:562-577.
4. Lindstedt, S. and Lindstedt, G. 1961. Distribution and excretion of carnitine in the rat. *Acta Chem. Scand.* 15:701-702.
5. Rebouche, C.J. and Engel, A.G. 1983. Carnitine metabolism and deficiency syndromes. *Mayo Clin. Proc.* 58:533-540.

6. Rebouche, C.J. and Paulson, D.J. 1986. Carnitine metabolism and function in humans. *Ann. Rev. Nutr.* 6:41-66.

7. Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D. 1989. *The Metabolic Basis of Inherited Disease*. New York: McGraw-Hill.

8. Schaub, J., Van Hoof, F. and Vis, H.L. 1991. *Inborn Errors of Metabolism*. New York: Raven Press.

9. Marzo, A., Arrigoni Martelli, E., Mancinelli, A., Cardace, G., Corbelletta, C., Bassani, E. and Solbiati, M. 1991. Protein binding of L-carnitine family components. *Eur. J. Drug Met. Pharmacokin.*, Special Issue III: 364-368.

10. Rebouche, C.J. 1991. Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. *Metabolism* 40:1305-1310.



Distributed by:


Hi-Tech Pharmacal Co., Inc.

Amityville, NY 11701

**PREVIOUS EDITION IS OBSOLETE**

**Date of Issue: 04/18 GTOPI-5**

**Package/Label Display Panel**



AKORN NDC 50383-172-90

Levocarnitine Tablets USP

330 mg tablets

Rx only 90 tablets

## LEVOCARNITINE

levocarnitine tablet

### Product Information

|                                |                         |                           |               |
|--------------------------------|-------------------------|---------------------------|---------------|
| <b>Product Type</b>            | HUMAN PRESCRIPTION DRUG | <b>Item Code (Source)</b> | NDC:50383-172 |
| <b>Route of Administration</b> | ORAL                    |                           |               |

**Active Ingredient/Active Moiety**

| Ingredient Name  | Basis of Strength | Strength |
|--|-------------------|----------|
| LEVOCARNITINE (UNII: 0G389FZZ9M) (LEVOCARNITINE - UNII:0G389FZZ9M) | LEVOCARNITINE     | 330 mg   |

**Inactive Ingredients**

| Ingredient Name                               | Strength |
|---|----------|
| MAGNESIUM STEARATE (UNII: 70097M6I30)         |          |
| MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) |          |
| POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)      |          |

**Product Characteristics**

|          |       |              |          |
|----------|-------|--------------|----------|
| Color    | WHITE | Score        | no score |
| Shape    | ROUND | Size         | 13mm     |
| Flavor   |       | Imprint Code | LC;77    |
| Contains |       |              |          |

**Packaging**

| # | Item Code        | Package Description                                     | Marketing Start Date | Marketing End Date |
|---|------------------|---|----------------------|--------------------|
| 1 | NDC:50383-172-90 | 9 in 1 CARTON   | 11/01/2005           |                    |
| 1 |                  | 10 in 1 BLISTER PACK; Type 0: Not a Combination Product |                      |                    |

**Marketing Information**

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------|--|----------------------|--------------------|
| NDA                | NDA018948                                | 11/01/2005           |                    |

**Labeler** - Akorn (117696873)**Registrant** - Akorn Operating Company LLC (117693100)**Establishment**

| Name             | Address | ID/FEI    | Business Operations    |
|------------------|---------|-----------|------------------------|
| Alfasigma, S.p.A |         | 438538098 | MANUFACTURE(50383-172) |

Revised: 11/2022

Akorn